A61P 33 - Antiparasitic agents

Patents for A61P 33 - Antiparasitic agents (21,787)
12/2002
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020182177 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182176 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine)
12/05/2002	US20020182174 Methods and compositions for promoting the maturation of monocytes
12/05/2002	CA2449014A1 Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1262482A1 Novel compound having antimalarial activity
12/04/2002	EP1262186A1 Azalide antibiotic compositions
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261707A1 5ht3 receptors of nematodes, polynucleotide molecules encoding same, and antagonists thereof
12/04/2002	EP1261605A1 Benzoxazole derivatives as tnf and pde iv inhibitors
12/04/2002	EP1261604A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
12/04/2002	EP1261603A1 Flavone derivatives, preparation method and use as medicines
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261378A2 Biodegradable immunomodulatory formulations and methods for use thereof
12/04/2002	EP1261366A1 Adjuvant treatment by in vivo activation of dendritic cells
12/04/2002	EP1261355A1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
12/04/2002	EP1261336A2 Il-8 receptor antagonists
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261328A1 Il-8 receptor antagonists
12/04/2002	EP1005342B1 Pharmaceutical compositions of tizoxanide and nitazoxanide
12/04/2002	EP0719285B1 Il8 inhibitors
12/04/2002	CN1382445A Veterinary licking antihelmintic
12/04/2002	CN1382375A Pediculus and nit killing compsns. and method for killing head pediculus and its nit
12/03/2002	US6489448 Antibody to a protein with thiol specific antioxidant (tsa) activity; vaccines
12/03/2002	US6489349 Treating an autoimmune disorder with an alkylamine substituted pyridine
12/03/2002	US6489303 Anthelmintic composition
11/2002
11/30/2002	CA2387821A1 Azalide antibiotic compositions
11/28/2002	WO2002095029A2 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	WO2002094814A1 3,5-diamino-1,2,4-triazoles as kinase inhibitors
11/28/2002	WO2002094293A1 Method for the destruction of oocysts
11/28/2002	WO2002094288A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/28/2002	WO2002094250A2 Therapeutic uses of lna-modified oligonucleotides in infectious diseases
11/28/2002	WO2002094221A1 Emulsion and dispersion formulations and method
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002	WO2001089497A3 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020177697 Immunity to trypanosomatids species
11/28/2002	US20020176904 Antiprotozal composition
11/28/2002	DE10125763A1 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
11/28/2002	DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002	CA2447608A1 Method for the destruction of oocysts
11/28/2002	CA2447170A1 Emulsion and dispersion formulations and method
11/28/2002	CA2446398A1 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	CA2443068A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/27/2002	EP1260590A1 Method of screening substance specifically inhibiting non-mevalonate pathway
11/27/2002	EP1259611A2 G-protein coupled receptors
11/27/2002	EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002	EP1259250A1 Endoparasiticidal agents
11/27/2002	EP1259244A1 Veterinary compositions for the treatment of parasitic diseases
11/27/2002	EP0708648B1 Inhibition of nitric oxide production by retinoic acid
11/27/2002	CN1382216A DNA coding for beta-tubulin and use thereof
11/27/2002	CN1382157A Therapeutic compounds comprised of anti-FC receptor binding agents
11/27/2002	CN1382150A Hydromycin derivatives
11/27/2002	CN1382149A Hygromycin A prodrugs
11/27/2002	CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002	CN1382061A Pharmaceutical compositions for oral and topical administration
11/27/2002	CN1382056A Lactic acid bacteria for treatment and/or prophylaxis of glardiasis
11/26/2002	US6486199 Spiro and dispiro 1,2,4-trioxolane antimalarials
11/26/2002	US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/26/2002	CA2095214C Agents for the treatment of diseases caused by parasitic protozoa and neoplastic diseases
11/26/2002	CA2087164C Target specific antibody-superantigen conjugates and their preparation
11/26/2002	CA2076465C Cell binding agent conjugates of analogues and derivatives of cc-1065
11/22/2002	WO2002094843A1 Crystal forms of azithromycin
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092628A2 Plasmodium falciparum antigens and vaccine and diagnostic uses thereof
11/21/2002	WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002	WO2002092589A2 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments
11/21/2002	WO2002092568A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	WO2002092563A2 Protease inhibitors
11/21/2002	WO2002092552A2 Benzamidoacetonitriles and their use as antiparasitics
11/21/2002	WO2002092079A1 Utilization of selective indirubin derivatives as vegf-r inhibitors
11/21/2002	WO2002092032A1 Use of 3-position cyclosporin derivatives for hair growth
11/21/2002	WO2002092013A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	WO2002091996A2 Methods for treating cancer
11/21/2002	WO2002091992A2 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002	WO2002057246A3 Inhibitors of cruzipain and other cysteine proteases
11/21/2002	WO2002022169A3 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
11/21/2002	US20020173662 Parasiticidal pyrazoles
11/21/2002	US20020173658 Administering to a mammal a substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines to reduce the levels of tumor necrosis factor-alpha to treat autoimmune diseases
11/21/2002	US20020173655 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal
11/21/2002	US20020173654 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents
11/21/2002	US20020173515 Antiproliferative agents
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173473 Organic compounds

1 ... 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 ... 218